Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Convalescent Plasma for Moderate COVID-19
NCT04516954Phase 1Completed
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by Vinmec Research Institute of Stem Cell and Gene Technology. Primary endpoint: Evaluate the safety at Day 28. Started Aug 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04516954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516954.